John L. Miclot
President and Chief Executive Officer
Mr. Miclot has served as Tengion's President and Chief Executive Officer since 2011, and brings nearly 25 years of healthcare industry experience and leadership to the Company. Prior to leading CCS Medical, Mr. Miclot served as Chief Executive Officer of Philips Home Healthcare Solutions following the acquisition of Respironics, Inc. by Royal Philips. Mr. Miclot spent 10 years in senior roles at Respironics, ultimately serving as President and Chief Executive Officer from 2003 to 2008. While in that role, Mr. Miclot led Respironics to record annual revenues of more than $1 billion. Mr. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies, Inc., a medical device company. Mr. Miclot served in various positions at Healthdyne from 1995 to 1998, including Senior Vice President, Sales and Marketing. Earlier in his career, he held sales and marketing roles at Medex, Ohmeda, Baxter Edwards, and DeRoyal Industries. Mr. Miclot is a director of Wright Medical Group, Inc. and Dentsply International Inc., and serves as Chairman of the Board of Directors of Breathe Technologies, Inc. He is also a director of the Pittsburgh Zoo & PPG Aquarium and Burger King Cancer Caring Center. He earned his B.B.A. in marketing from the University of Iowa.
Tim Bertram, D.V.M., Ph.D.
President, Research and Development and Chief Scientific Officer
Dr. Bertram has served as Tengion's Chief Scientific Officer since 2004. Prior to joining Tengion, Dr. Bertram was senior scientific executive at Pfizer, SmithKline Beecham Pharmaceuticals, and Procter & Gamble Co; a faculty member at the University of Illinois; and a visiting scientist to the National Institutes of Health. Dr. Bertram has been a leadership-mentor to scientists in government, academics, and industry. His experience includes worldwide leadership of multidisciplinary scientific teams for the pharmaceutical industry, government and private foundations focusing on resolution of challenges in pharmaceutical productivity and defining industrial applications of advanced molecular, cellular and whole organism technologies for selecting optimal therapeutic candidates with experience in discovery, development and registration of small molecules, cell-based therapies and regenerative medical products. Organizational leadership activities have included Pharmaceutical R&D sites in both the US and Europe with responsibility for developing and setting Discovery and Development strategies. Most recently, Dr. Bertram was responsible for operational oversight of large discovery and development organizations in disciplines including genomics, proteomics, discovery, development, comparative medicine and business support groups to enable therapeutic agent development. His organizations have supported new medicine portfolios that included Gastrointestinal, CNS, Cancer, Respiratory, Infectious, Immunologic, Cardiovascular, Urology, Nephrology and Metabolic diseases with the preparation of regulatory submissions for agencies in major markets around the world. Dr. Bertram holds active academic appointments and industrial advisory positions at leading national and European educational institutions, International Society of Stem Cell Research, Tissue Engineering Regenerative Medical International Society Industrial Liaison Committee, Industrial Business Advisory Board and Industrial Advisory Committee of UCLA's Bioengineering Department and industry. Dr. Bertram is a member of journal editorial boards for Tissue Engineering and, Regenerative Medicine. He has over 150 scientific communications and patents focusing on the cellular and molecular basis of diseases and tissue and organ regeneration involving the respiratory, urogenital, renal and gastrointestinal organ systems.
A. Brian Davis
Chief Financial Officer and Vice President, Finance
Mr. Davis joined Tengion as Chief Financial Officer in 2010, after 15 years with Neose Technologies, Inc., a biopharmaceutical company using enzymatic technologies to develop improved protein therapeutics. At its peak, Neose employed 200 individuals, including cGMP production, development and research personnel at three sites. Mr. Davis advanced from Controller to SVP and CFO at Neose, and brings highly relevant experience to Tengion including raising over $300 million in public and private equity and debt, financial evaluation of business development transactions, treasury and cash management, SEC reporting, Sarbanes-Oxley compliance, and investor relations. Mr. Davis holds a BS in Accounting from Trenton State College and an MBA from the Wharton School of the University of Pennsylvania. He is a Certified Public Accountant.
Deepak Jain, Ph.D.
Chief Technology Officer
Dr. Jain joined Tengion in 2004. and has over 28 years of experience in biotechnology, tissue engineering and regenerative medicine bioprocess research & development and GMP manufacturing. Before joining Tengion, Dr. Jain was Executive Director of Process Development and Manufacturing Technical Support at Advanced Tissue Sciences responsible for development of human-based tissue products for therapeutic applications in the skin, cartilage and cardiovascular areas. Dr. Jain has held several positions of increasing technical and management responsibility at Merck and Johnson & Johnson, leading the development of biotechnology products with a focus on recombinant proteins. Dr. Jain was instrumental in the development and manufacturing support of J&J’s multi-billion dollar product for the treatment of anemia. More recently, Dr. Jain was as a full-time consultant for Baxter Corporation responsible for establishing a commercial manufacturing facility overseas for a marketed recombinant protein. Dr. Jain is accomplished at directing product development from research to the clinic, process scale-up, technology transfers, GMP facility design, process validation and manufacturing of biotechnology-derived recombinant proteins and tissue engineered regenerative medicine products. He is highly experienced in regulatory CMC submissions for biologics, devices and combination products. Since joining Tengion in 2004, Dr. Jain has been responsible for bioprocess research & development and clinical manufacturing.
Dr. Jain serves as the Chairman of Cell Therapy Ad hoc Advisory Panel for United States Pharmacopoeia and is a member of USP’s Biologics & Biotechnology Expert Committee. Dr. Jain has also served as Chairman of the American Society for Testing and Materials Task Group on Preservation of Cells and Tissue Engineered Medical Product’s with Cells. Dr. Jain has over 40 publications, presentations and abstracts, two book chapters and many patents in the field biologics, tissue engineering and regenerative medicine. Dr. Jain received a PhD from the Indian Institute of Technology, Delhi in Biochemical Engineering.